Each business day, TheStreet.com Ratings compiles a list of the top five stocks in one of five categories -- fast-growth, all-around value, large-cap, mid-cap and small-cap -- based on data from the close of the previous trading session. Today, small-cap stocks are in the spotlight.
These are stocks of companies that have market capitalizations of $50 million to $500 million that rank near the top of all stocks rated by our proprietary quantitative model, which looks at more than 60 factors. The stocks must also be followed by at least one financial analyst who posts estimates on the Institutional Brokers' Estimate System. They are ordered by their potential to appreciate.
Note that no provision is made for off-balance-sheet assets such as unrealized appreciation/depreciation of investments, market value of real estate or contingent liabilities that might affect book value. This could be material for some companies with large underfunded pension plans.
and its subsidiaries develop, manufacture and market products dedicated to food and animal safety. Our buy rating for Neogen has not changed since February 2003, based on strengths such as the company's robust revenue growth, impressive record of earnings per share growth, and expanding margins.
For the first quarter of fiscal 2009, the company reported that its revenues, net income and EPS all represented quarterly records. Revenue growth was reported at 25.7% year over year, with revenues appearing to help boost EPS by 17.2%. Net income also increased, rising 24%, from $3.01 million in the first quarter of fiscal 2008 to $3.73 million in the most recent quarter. Neogen attributed its record results to the assimilation of recent acquisitions and significant growth in the company's primary product lines. Additionally, the company's gross profit margin is rather high at 54.7%, but Neogen has managed to decrease this number over the last year.
Neogen's sale price has not changed very much compared to where it was trading a year ago due to the relatively weak overall performance of the market and the company's recent mixed results. However, it is currently trading at a price that is somewhat expensive compared to the rest of its industry. Due to the strengths detailed here and a lack of significant weaknesses, we feel that higher price level is justified at this time.
processes and markets culinary, snack, in-shell and ingredient nuts. We upgraded Diamond Foods from a hold to a buy in July 2008 on the basis of the company's impressive record of EPS growth, increases in revenue and net income and largely solid financial position.
For the fourth quarter of fiscal 2008, the company reported that its revenue increased slightly, rising 0.6% year over year. However, net income grew significantly, surging 240.3% from $770,000 in the fourth quarter of fiscal 2007 to $2.63 million in the most recent quarter. EPS improved from 5 cents to 16 cents, and we feel that the company should be able to continue its trend of positive EPS growth seen in the past year. Diamond has a very low debt-to-equity ratio of 0.14, which implies that the company has successfully managed its debt levels. In addition, the company appears to be able to avoid any short-term cash problems. During the quarter, the company took steps to place its snack business in a better position in the market by introducing new products and adding new distribution in key markets. As a result, snack sales improved 3.0%, finishing the year 11% higher than full-year fiscal 2007 results. Culinary sales grew 39% in the quarter and 1% for the full year compared with last year.
Based on its fourth quarter and full-year fiscal 2008 results, the company released guidance for the year ahead. Management anticipates full-year EPS in the range of $1.20 to $1.27, with net sales expected to be between $585 million and $615 million. Although the company shows low profit margins, we feel that the strengths detailed above outweigh any potential weakness exhibited by Diamond at this time.
Tompkins Financial Corporation
is the corporate parent of three community banks: Tompkins Trust Company, The Bank of Castile and Mahopac National Bank.
We have rated Tompkins Financial a buy since October 2007 on the basis of its notable return on equity, expanding profit margins, increased in net income and revenue and solid stock price performance. For the third quarter of fiscal 2008, the company reported revenue growth of 6.3% year over year. This appears to have helped boost EPS, which rose 15.7% to a record level for the company. EPS was reported as 81 cents for the third quarter, compared with 70 cents in the prior year's quarter. Net income also increased, rising 16.6% from $6.81 million to $7.93 million. Return on equity improved slightly over where it was a year ago, which can be construed as a modest strength for the company. Tompkins' return on equity of 14.1% exceeded the average for the Commercial Banking industry. The company's stock price has risen over the past year, reflecting earnings growth and other positive factors.
Management stated that the company was fortunate to operate in markets that were not as heavily impacted by the national and global economic crisis as some areas of the country. A focus on long-term results allowed Tompkins to continue to perform well in challenging economic times, allowing the company to grow its business while still avoiding high-profile risky loans and investments. Although the company's stock is currently trading at a premium valuation, we feel that its strengths justify the higher price levels at this time.
, which does business as 1-800-PetMeds, markets and sells prescription and nonprescription pet medications, along with other health products for dogs, cats and horses. We have rated PetMed Express a buy since November 2004 due to such strengths as its solid stock price performance, growth in net income and revenue and largely solid financial position.
The company announced on Oct. 20 that its revenue rose 15.6% year over year in the second quarter of fiscal 2008. This growth helped lead to EPS growth of 38.9% when compared with the same quarter last year. The company has, in fact, demonstrated a pattern of positive EPS growth over the past two years, and we feel that this trend should continue. Net income also improved in the second quarter, rising 28.6% from $4.53 million in the second quarter of fiscal 2007 to $5.82 million in the most recent quarter. Strong earnings growth was key to helping drive the stock price higher over the last year, although other factors naturally played a role, as well. In addition, PetMed Express has no debt to speak of and a quick ratio of 5.53, factors which indicate the successful management of debt levels and the ability to cover short-term cash needs.
Management announced that it was pleased that its efforts to reduce operating expenses as a percentage of sales helped lead the company to a highly profitable second quarter. Looking ahead, PetMed Express plans to focus on capturing additional market share, as well as improving reorders and customer service levels. Although no company is perfect, we do not currently see any significant weaknesses that are likely to detract from the future financial performance of this company.
is a provider of information technology services and solutions to U.S. federal government agencies. NCI has been rated a buy since February 2008 based on its healthy growth in revenue and net income, solid stock price performance, impressive record of EPS growth, and return on equity.
For the third quarter of fiscal 2008, the company reported revenue growth of 18.7% year over year. This growth represents record revenue results for the company, and appears to have trickled down to NCI's bottom line, improving EPS by 28.0%. EPS increased from 25 cents in the third quarter of fiscal 2007 to 32 cents in the most recent quarter. Net income also increased, rising 31.6% from $3.34 million to $4.40 million. Return on equity improved slightly from 16.18% to 16.58%. NCI's strong earnings growth has helped the stock price climb higher over the past year.
Management announced that it was pleased with what it considered excellent quarterly results and considers NCI well-placed in its markets and with its customers for fiscal 2009. The company is confident about its business model and plans to continue with its strategic plan of focusing on organic growth supplemented with strategic acquisitions that generate long-term, sustainable value. While an overall down market can negatively affect any stock, we feel that the company has good upside potential in any other market, despite the fact that it has already risen in the past year. In addition, we believe that the strengths detailed above outweigh the fact that the company shows low profit margins.
Our quantitative rating is based on a variety of historical fundamental and pricing data and represents our opinion of a stock's risk-adjusted performance relative to other stocks. However, the rating does not incorporate all of the factors that can alter a stock's performance. For example, it doesn't always factor in recent corporate or industry events that could affect the stock price, nor does it include recent technology developments and competitive dynamics that may affect the company. For those reasons, we believe that a rating alone cannot tell the whole story and that it should be part of an investor's overall research.
This article was written by a staff member of TheStreet.com Ratings.